Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gp100 antigen
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 45 for your search:
Start Over
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02897, CDR0000066963, 99-C-0051, T98-0085, CCCGHS-NCI-T98-0085, NCI-T98-0085, NCI-99-C-0051B, NCT00019682
Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067568, U10CA021115, ECOG-4697, SWOG-E4697, E4697, NCT00005034
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000066097, DUMC-719975, DUMC-0932-99-5R2, DUMC-759-99-5R2, UVA-HIC-7454, NCI-G98-1398, NCT00003229
Phase I/II Pilot Study of a Multi-Epitope Peptide Vaccine With Sargramostim (GM-CSF) Plasmid DNA Immune Adjuvant in Patients With Stage IIB, IIC, III, or IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Any age (weight > 25 kg)
Sponsor: NCI
Protocol IDs: MSKCC-00142A, 5906, NCI-5906, NCT00085137
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 79
Sponsor: NCI, Other
Protocol IDs: 7621, IRB-HSR 7621, NCI-G98-1389, UVACC-HIC-7621, UVA-HIC-7621, NCT00003222
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066176 (10M-97-1), LAC-USC-10M971, LAC-USC-FDR001101, NCI-T97-0100, T97-0100, NCT00003274
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066310 (10M-97-3), LAC-USC-10M973, NCI-G98-1432, NCI-T97-0099, T97-0099, NCT00003339
Phase II Study of Immunization With gp100 Antigen With Endoplasmic Reticulum Insertion Signal Sequence Alone or in Combination With Interleukin-2 in Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0142, NCI-T98-0036, T98-0036
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 990158, 99-C-0158, NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942, NCT00001832
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000067391, NCI-99-C-0159, NCI-T99-0079, T99-0079, NCT00019994
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02337, CLB-509901, U10CA031946, CDR0000067886, CALGB-509901, NCT00005949
Vaccine Therapy in Treating Patients With Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000068299, NCI-00-C-0216, NCI-2391, 2391, NCT00020358
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069220 (10M-01-1), LAC-USC-10M011, LAC-USC-IRB-013030, NCI-5506, 5506, NCT00031733
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 030172, 03-C-0172, NCI-03-C-0172, NCI-6211, 6211, NCT00062218, NCT00059475
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000335441, NCI-03-C-0299, NCI-6210, 6210, NCT00072085
Phase II Randomized Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) With or Without gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0083, MDX-010-19, NCI-6532, 6532, NCT00077532
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000365467, P30CA076292, P30CA014089, MCC-15241, MDX010-16, NCI-6446, CA184-016, 6446, LAC-USC-10M036, NCT00084656
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: 10M-03-3, NCI-2012-02593, CDR0000367485, LAC-USC-10M033, LAC-USC-IRB-942010, NCI-6451, 6451, NCT00085189
Start Over